Renin-Angiotensin System Inhibitors and the COVID-19 Pandemic.

Muntner I et al. i in a large cohort study evaluated indirectly, the RAS Inhibitor medication controversy, whether it led to a significant number of patients discontinuing RAS inhibitor treatment.[22] The findings are important to inform responses to future public health emergencies. Despite the controversy at the beginning of the COVID-19 pandemic, overwhelming scientific evidence has shown RAS inhibitors to be safe and beneficial in COVID-19. [Extracted from the article]